Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
Louis Huang,David J. Nikolic-Paterson,Yingjie Han,Elyce Ozols,Frank Y. Ma,Morag J. Young,Greg H. Tesch +6 more
TLDR
Myeloid deficiency of MR provides protection similar to eplerenone in this disease, and MR signaling in myeloid cells, but not podocytes, contributes to the progression of renal injury in mouse GN.Abstract:
Clinical and experimental studies have shown that mineralocorticoid receptor (MR) antagonists substantially reduce kidney injury. However, the specific cellular targets and mechanisms by which MR antagonists protect against kidney injury must be identified. We used conditional gene deletion of MR signaling in myeloid cells (MR flox/flox LysM Cre mice; MyMRKO) or podocytes (MR flox/flox Pod Cre mice; PodMRKO) to establish the role of MR in these cell types in the development of mouse GN. Accelerated anti–glomerular basement membrane GN was examined in groups of mice: MyMRKO, PodMRKO, wild-type (WT) littermates, and WT mice receiving eplerenone (100 mg/kg twice a day; EPL-treated). At day 15 of disease, WT mice had glomerular crescents (37%±5%), severe proteinuria, and a 6-fold increase in serum cystatin-C. MyMRKO, PodMRKO, and EPL-treated mice with GN displayed proteinuria similar to that in these disease controls. However, MyMRKO and EPL-treated groups had a 35% reduction in serum cystatin-C levels and reduced crescent numbers compared with WT mice, whereas PodMRKO mice were not protected. The protection observed in MyMRKO mice appeared to result predominantly from reduced recruitment of macrophages and neutrophils into the inflamed kidney. Suppression of kidney leukocyte accumulation in MyMRKO mice correlated with reductions in gene expression of proinflammatory molecules (TNF- α , inducible nitric oxide synthase, chemokine (C-C motif) ligand 2, matrix metalloproteinase - 12), tubular damage, and renal fibrosis and was similar in EPL-treated mice. In conclusion, MR signaling in myeloid cells, but not podocytes, contributes to the progression of renal injury in mouse GN, and myeloid deficiency of MR provides protection similar to eplerenone in this disease.read more
Citations
More filters
Journal ArticleDOI
Macrophages: versatile players in renal inflammation and fibrosis
TL;DR: The induction of MMT, via the Src-centric regulatory network mediated by transforming growth factor-β1 (TGFβ1)–Smad3, serves as a key checkpoint in the progression of chronic inflammation to renal fibrosis.
Journal ArticleDOI
Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology
F. Jaisser,N. Farman +1 more
TL;DR: Excess mineralocorticoid signaling now appears deleterious in the progression of pathologies that may lead to end-stage organ failure and could therefore benefit from the repositioning of pharmacological MR antagonists.
Journal ArticleDOI
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Rajiv Agarwal,Peter Kolkhof,George L. Bakris,Johann Bauersachs,Hermann Haller,Takashi Wada,Faiez Zannad +6 more
TL;DR: Overall, nonsteroidal MRAs appear to demonstrate a better benefit–risk ratio than steroidal MRAs, where risk is measured as the propensity for hyperkalaemia.
Journal ArticleDOI
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
TL;DR: The available preclinical and clinical data support a benefit of using MRAs in CKD, an approach that should be further explored in future clinical trials.
Book ChapterDOI
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
Peter Kolkhof,Frederic Jaisser,So Young Kim,Gerasimos Filippatos,Christina Nowack,Bertram Pitt +5 more
TL;DR: Novel, potent, and selective non-steroidal MRAs (third generation) were identified in drug discovery campaigns and a few entered clinical development recently, one of these is finerenone with different physicochemical, pharmacokinetics, and pharmacological properties in comparison with the steroidal MRAs.
References
More filters
Journal ArticleDOI
Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis.
Yingjie Han,Yingjie Han,Frank Y. Ma,Frank Y. Ma,Gregory H Tesch,Gregory H Tesch,Carl L. Manthey,David J. Nikolic-Paterson,David J. Nikolic-Paterson +8 more
TL;DR: It is demonstrated that macrophages contribute to renal dysfunction and tissue damage in established crescentic glomerulonephritis as it progresses from the acute inflammatory to a chronic fibrotic phase.
Journal ArticleDOI
Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions.
Sun Ha Lee,Tae Hyun Yoo,Bo Young Nam,Dong Ki Kim,Jin Ji Li,Jin Ji Li,Dong Sub Jung,Seung Jae Kwak,Dong Ryeol Ryu,Seung Hyeok Han,Jung Eun Lee,Sung Jin Moon,Dae Suk Han,Shin Wook Kang +13 more
TL;DR: The findings suggest that a local aldosterone system is activated and is involved in podocyte apoptosis under diabetic conditions.
Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions
Sun Ha Lee,Tae Hyun Yoo,Bo Young Nam,Dong Ki Kim,Jin Ji Li,Jin Ji Li,Dong Sub Jung,Seung Jae Kwak,Dong Ryeol Ryu,Seung Hyeok Han,Jung Eun Lee,Sung Jin Moon,Dae Suk Han,Shin Wook Kang +13 more
TL;DR: In this article, the role of aldosterone in podocyte injury has been explored in diabetic nephropathy (DN) and showed that mineralocorticoid receptor (MCR) blocker reduces proteinuria.
Journal ArticleDOI
Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury
Andy K.H. Lim,Frank Y. Ma,David J. Nikolic-Paterson,Arthur R Kitching,Merlin C. Thomas,Gregory H Tesch +5 more
TL;DR: Results show that lymphocytes contribute to the development of diabetic albuminuria, which may partly arise from increasing glomerular macrophage activation and podocyte damage, and suggest that innate immunity rather than adaptive immune responses are the major inflammatory contributor to the progression of diabetic renal injury.
Journal ArticleDOI
The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
Rena Eudy,Vaishali Sahasrabudhe,Kevin Sweeney,Meera Tugnait,Amanda King-Ahmad,Kristen Near,Paula M. Loria,Mary Ellen Banker,David W. Piotrowski,Carine M. Boustany-Kari,Carine M. Boustany-Kari +10 more
TL;DR: Urinary Na+/K+ and plasma aldosterone appear to be translatable biomarkers of MR antagonism following administration of single or multiple doses of compound, respectively.